{
  "source": "PA-Med-Nec-Diclegis.txt",
  "chunks": [
    "UnitedHealthcare Pharmacy\nClinical Pharmacy Programs\nProgram Number 2024 P 2024-12\nProgram Prior Authorization/Medical Necessity\nMedication Bonjesta®* (doxylamine/pyridoxine extended-release), Diclegis®*\n(doxylamine/pyridoxine delayed-release)\nP&T Approval Date 4/2014, 4/2015, 3/2016, 4/2017, 7/2018, 9/2019, 10/2020, 11/2021,\n12/2022, 1/2024\nEffective Date 4/1/2024\n1. Background:\nBonjesta and Diclegis are fixed dose combinations of doxylamine and pyridoxine approved\nby the Food and Drug Administration (FDA) for the treatment of nausea and vomiting of\npregnancy in women who have not responded to conservative management.\n2. Coverage Criteriaa:\n1. Initial Authorization\na. Bonjesta* or Diclegis* will be approved based on all of the following criteria:\n1. Diagnosis of nausea and vomiting associated with pregnancy\n-AND-\n2. Documented failure or contraindication to lifestyle modifications (e.g., diet,\navoidance of triggers)\n-AND-\n3. Documented trial and failure or contraindication to a five-day trial of over-the-\ncounter doxylamine taken together with pyridoxine (i.e., not a combined dosage\nform, but separate formulations taken concomitantly).\nAuthorization will be issued for 9 months.\na State mandates may apply. Any federal regulatory requirements and the member specific\nbenefit plan coverage may also impact coverage criteria. Other policies and utilization\nmanagement programs may apply.\n*Bonjesta and Diclegis are typically excluded from coverage. Please refer to plan specifics to determine\nexclusion status.\n© 2024 United HealthCare Services, Inc.\n1\n3. Additional Clinical Rules:\n• Supply limitations may be in place.\n• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-\nauthorization based solely on previous claim/medication history, diagnosis codes (ICD-10)\nand/or claim logic. Use of automated approval and re-approval processes varies by program\nand/or therapeutic class.\n4. References:\n1. Diclegis [package insert]. Princeton, NJ: Duchesnay USA,",
    " (ICD-10)\nand/or claim logic. Use of automated approval and re-approval processes varies by program\nand/or therapeutic class.\n4. References:\n1. Diclegis [package insert]. Princeton, NJ: Duchesnay USA, Inc.; June 2023.\n2. \"ACOG (American College of Obstetrics and Gynecology) Practice Bulletin: Nausea and\nvomiting of pregnancy.\" Obstetrics and gynecology 2018; 131(1) e15-e30.\n3. Herrell HE. Nausea and vomiting of pregnancy. Am Fam Physician 2014 Jun\n15;89(12):965-970.\n4. Bonjesta [package insert]. Princeton, NJ: Duchesnay USA, Inc.; October 2022.\nProgram Prior Authorization/Medical Necessity – Bonjesta and Diclegis\nChange Control\n4/2014 New Program\n4/2015 Annual review with administrative changes.\n3/2016 Increased initial authorization from 3 to 9 months and removed\nreauthorization criteria.\n7/2016 Added Indiana and West Virginia coverage information.\n11/2016 Administrative change. Added California coverage information.\n4/2017 Annual Review. Removed dosing for over-the-counter products.\nRemoved requirement for trial of dimenhydrinate and pyridoxine.\nUpdated references. State mandate reference language updated.\n7/2018 Added Bonjesta to criteria. Updated to note Bonjesta and Diclegis are\ntypically excluded from coverage.\n9/2019 Annual review. Updated references, added automation language, and\nclarified trial/failure language with separate dosage forms.\n10/2020 Annual review. Updated reference, clarified Diclegis dosage form.\n11/2021 Annual review with no changes.\n12/2022 Annual review with no changes.\n1/2024 Annual review with no changes.\n© 2024 United HealthCare Services, Inc.\n2"
  ]
}